According to the Minister of Health Vlastimil Válek (TOP 09), this could happen next week. According to him, there is no problem in the price or in the payment of the deposit, which was also confirmed on Thursday by the Minister of Finance Zbyněk Stanjura (ODS).
–
The infusions have helped many people, saved many lives
Pavel Dlouhý, Chairman of the Society of Infectious Medicine
—
But the delivery will come at a time when the beginning of the omicron wave should be over. “This antiviral drug can no longer hit the omicron wave. We would have to sign the contract before December 17, “Válek told ČT.
–
He does not see the mistake of the previous government in this, but rather the strict conditions that Pfizer has set for all states. Válek considers the fact that the drugs would arrive before the predominance of omicron in the Czech Republic to be excluded and is striving for delivery at least in March.
–
Some media have pointed to the 250 million advance that the company is asking for drugs, which could be a problem in the temporary budget. Válek refused this again on Thursday. According to him, the 15% deposit required by the company is not a problem.
–
The Czechia is to pay a total of 1.8 billion crowns for the pre-negotiated amount, as the Minister of Finance specified on Thursday. “We have found a solution with the Minister, there is no problem,” Stanjura said.
–
Cocktails are no longer enough
Covid antivirals will rely the most in the coming weeks and maybe months. In the case of omicron, it should replace the hitherto very effective infusions of monoclonal antibodies. According to studies, they do not work against the new variant.
–
“These are great drugs that have helped many people, saved many lives. As long as we have the last patient with a delta, these antibodies still have their meaning, “emphasized Pavel Dlouhý, Chairman of the Society of Infectious Medicine.
–
The risk of hospitalization in the delta after early treatment is reduced by 70 percent. In the case of omicron, remdesivir and molnupiravir are currently available in the Czech Republic for high-risk patients at risk of severe covid.
–
Remdesivir, the first covid drug in 2020, has now been re-approved for non-hospitalized patients. “It’s more complicated because you have to get an infusion for three days in a row, but it’s highly effective: 85 percent risk reduction,” Dlouhy explained.
–
Molnupiravir has been available in the Czech Republic under the name Lagevrio since the end of December, when the first 5,000 packs of capsules taken at home have been infected.
–
Gradually, the drug reaches the first high-risk patients, who are met by a general practitioner or an outpatient if they meet the criteria. Medicines are available at most hospital pharmacies.
–
The University Hospital in Pilsen issued capsules of capsules to eleven patients, fourteen packages were issued by the University Hospital in Prague Motol and six by the University Hospital in Ostrava.
–
According to Dlouhý, who is also a member of the National Institute for Pandemic Management, another type of monoclonal antibody called evusheld, which is intended for people with severe immune disorders, is due to arrive in January.
—
